Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma.
Vásquez
Luz Maria
LM
Somani
Sohel
S
Altomare
Filiberto
F
Simpson
E Rand
ER
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001918:Brachytherapy / Q000009:adverse effects*; D002830:Choroid Neoplasms / Q000532:radiotherapy*; D005122:Exudates and Transudates; D005260:Female; D005451:Fluorescein Angiography; D015355:Glaucoma, Neovascular / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007429:Intraocular Pressure; D007457:Iodine Radioisotopes / Q000009:adverse effects; D007498:Iris / Q000098:blood supply; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007457:Iodine Radioisotopes; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab